Department of Dermatology and Pediatric Dermatology, National Center for Rare Skin Disorders, Saint-André and Pellegrin Hospitals, Bordeaux, France.
INSERM U1035, University of Bordeaux, Bordeaux, France.
G Ital Dermatol Venereol. 2019 Aug;154(4):435-443. doi: 10.23736/S0392-0488.18.06254-5. Epub 2019 Jan 16.
Antibody-based therapeutics targeting programmed cell death 1 (PD-1) have shown strong efficacy in the treatment of metastatic cancers as melanoma. However, restoring the immune function with these therapies to target cancer cells leads to immune side effects including immune cutaneous events. Vitiligo-like lesions in patients receiving anti-PD-1 is one of the most common skin adverse event reported and the incidence seems to be higher than in patients receiving other immune-checkpoints therapies. Initially described in patients with metastatic melanoma, vitiligo-like lesions have now been reported in other metastatic cancers treated with anti-PD-1. Several reports suggest that this side effect could be different from spontaneously occurring vitiligo and could be associated with increased response to the therapy and patients' survival. The aim of this review is to provide an overview of the clinical presentation of vitiligo-like lesions occurring in patients receiving anti-PD-1, and the hypothesis to explain the mechanism involved in the development of these lesions.
针对程序性细胞死亡 1（PD-1）的抗体治疗在治疗黑色素瘤等转移性癌症方面显示出强大的疗效。然而，这些疗法通过恢复免疫功能来靶向癌细胞，会导致免疫副作用，包括免疫皮肤事件。接受抗 PD-1 治疗的患者出现白癜风样病变是最常见的皮肤不良反应之一，其发生率似乎高于接受其他免疫检查点治疗的患者。最初在转移性黑色素瘤患者中描述，现在已经在接受抗 PD-1 治疗的其他转移性癌症患者中报告了白癜风样病变。有几项报告表明，这种副作用可能与自发性发生的白癜风不同，并且可能与对治疗的反应增加和患者的生存有关。本综述的目的是提供接受抗 PD-1 治疗的患者发生的白癜风样病变的临床表现概述，并提出解释这些病变发展机制的假说。
